Loading...
Market
ELEVIDYS best-selling gene therapy in US by end of 2024?
5
Resolution / Starting Odds
Yes • 33%
No • 34%
Top 3 but not best-selling • 33%
Market sales data from industry reports or financial databases
Story
Sarepta's ($SRPT) ELEVIDYS Gains Expanded FDA Approval for Duchenne Muscular Dystrophy Patients Ages 4 and Above
Jun 20, 2024, 09:04 PM
Sarepta Therapeutics ($SRPT) has announced that the US FDA has expanded the approval of its gene therapy, ELEVIDYS, for Duchenne Muscular Dystrophy (DMD) patients. The label expansion now includes both ambulatory and non-ambulatory patients who are at least 4 years old and have a confirmed mutation in the DMD gene. The non-ambulatory indication is under accelerated approval, while the ambulatory indication has been converted to full approval. This expansion marks a significant milestone for Sarepta Therapeutics and provides broader access to treatment for patients with DMD.
View original story
Similar markets
Positive • 33%
Neutral • 33%
Negative • 34%
Below $500M • 33%
$500M - $1B • 33%
Above $1B • 34%
Less than $500 million • 33%
$500 million to $1 billion • 34%
More than $1 billion • 33%
Less than $10 billion • 25%
$10 billion to $20 billion • 25%
$20 billion to $30 billion • 25%
More than $30 billion • 25%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Yes • 50%
No • 50%
Less than 5,000 • 25%
5,000 - 10,000 • 25%
10,000 - 15,000 • 25%
More than 15,000 • 25%
Less than 100 • 33%
100 to 500 • 34%
More than 500 • 33%
Proof-of-concept data achieved • 25%
Partnership announcement • 25%
Regulatory approval submission • 25%
No major milestone achieved • 25%